[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuromuscular-manifestations\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuromuscular-manifestations":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,87,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100640820","phase-1-hormones-outcomes-and-pain-pathways-in-exercise-study-100640820",false,"NCT07579182","Hormones, Outcomes, and Pain Pathways in Exercise Study","Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women","HOPE","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age of 18 to 60 years\n3. Assigned female sex at birth\n4. Right-handed by self-declaration\n5. Willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size between 32-40\"\n7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher\n8. An answer of \"NO\" to any item of the general health questions of the PARQ+\n9. No history of surgery to the: back, neck, or shoulders or joint replacement\n10. No history of implanted pacemakers or other stimulation devices\n11. No history of spinal cord injury (SCI)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Age 17 years old or younger or 61 years or older\n3. Assigned male sex at birth\n4. Left-handed by self-declaration\n5. Not willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size greater than 40\" or less than 32\"\n7. IPAQ-SF score of 1 or lower\n8. An answer of \"YES\" to any item of the general health questions of the PARQ+\n9. History of limb amputation (upper or lower extremity)\n10. Presence of open pressure sores on the upper or lower extremities\n11. Currently pregnant or lactating\u002Fbreastfeeding\n12. History of surgery to the: back, neck, or shoulders or joint replacement\n13. History of breast cancer and\u002For mastectomy\n14. History of implanted pacemakers or other stimulation devices\n15. History of spinal cord injury (SCI)\n16. History of joint disease including osteoarthritis and\u002For Rheumatoid Arthritis\n17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and\u002For Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies\n\nAdditional Inclusion Criteria for Intervention Group:\n\na. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)\n\nAdditional Inclusion Criteria for the Control Group:\n\na. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)",true,"FEMALE","18 Years","60 Years",{"count":22,"type":23},140,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.",[29,30,31,32,33,34,35,36,37,38,39,40,41],"Breast Pain","Mastalgia","Back Pain","Back Pain, Low","Neck Pain","Chest Pain","Activity, Motor","Healthy Aging","Weight, Body","Inflammation","Gonadal Steroid Hormones","Neuronal Plasticity","Neuromuscular Manifestations","RECRUITING","2026-05-28",{"date":45,"type":46},"2026-06-02","ACTUAL",{"date":48,"type":46},"2026-05-17",{"date":50,"type":23},"2029-09",{"name":52,"class":53},"University of Houston","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":4,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":24,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100596567","phase-2-a-study-to-evaluate-how-apitegromab-works-in-subjects-who-are-less-than-2-years-old-and-have-spinal-muscular-atrophy-100596567","NCT07047144","A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy","A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects \u003C2 Years Old With Spinal Muscular Atrophy (SMA)","OPAL","Inclusion Criteria:\n\n1. Is \\\u003C2 years old at the time of the informed consent\n2. Had a gestational age of ≥35 weeks and gestational body weight ≥2.0 kg at birth\n3. Has confirmed diagnosis of 5q autosomal recessive SMA\n4. Has confirmed presence of SMN2 gene copy(ies)\n5. Must have been treated with an approved SMN1-targeted therapy (ie, onasemnogene abeparvovec-xioi) or are continuing to be treated with an approved SMN2-targeted therapy (ie, nusinersen or risdiplam)\n6. Body weight for age is no less than 1st percentile based on the WHO Child Growth Standards at the Screening Visit\n7. Has delayed motor milestones for age attributed to SMA at the discretion of the Investigator or a CHOP-INTEND score \\\u003C55\n\nExclusion Criteria:\n\n1. Nutritional status that is not anticipated to be stable throughout the study or medical necessity for a gastric feeding tube, where most feeds are administered by this route\n2. Major orthopedic issues such as severe scoliosis or severe contractures or interventional procedure, including spine or hip surgery, which is considered to have the potential to substantially limit the ability of the subject to be evaluated on any motor function outcome measures, within 6 months before Screening or anticipated during the study\n3. Any other physical limitations (eg, the subject requires cast for contractures) that would prevent the subject from undergoing motor function outcome measures throughout the study.","ALL","2 Years",{"count":66,"type":23},52,[68],"PHASE2","This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK\u002FPD, efficacy, safety, and tolerability of apitegromab in subjects \\\u003C2 years old with 5q autosomal recessive SMA who have delayed motor milestones for their age attributed to SMA at the discretion of the Investigator or a Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score \\\u003C55.",[71,72,73,74,41,75],"Spinal Muscular Atrophy","SMA","Spinal Muscular Atrophy Type 2","Spinal Muscular Atrophy Type 3","Anti-myostatin","2026-04-29",{"date":78,"type":46},"2026-05-01",{"date":80,"type":46},"2025-09-15",{"date":82,"type":23},"2029-03",{"name":84,"class":85},"Scholar Rock, Inc.","INDUSTRY",25,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":24,"phases":95,"briefSummary":96,"conditions":97,"keywords":104,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100564264","phase-1-a-phase-1-study-of-anitocabtagene-autoleucel-for-the-treatment-of-subjects-with-non-oncology-plasma-cell-related-diseases-100564264","NCT06626919","A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","Inclusion Criteria:\n\n* Subject must be 18 years of age or older\n* Must have MGFA clinical classification Grades 2-4A at time of screening\n* Subject must have clinically active disease and requiring ongoing therapy for GMG\n* MG-ADL score 6 and QMG score \\>10 at screening\n* GMG specific autoantibodies must be above the reference laboratory ULN\n\nExclusion Criteria:\n\n* Subject is pregnant or breastfeeding\n* Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion\n* Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager\n* Previous thymectomy within 6 months of screening\n* Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator",{"count":94,"type":23},30,[26],"A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.",[98,41,99,100,101,102,103],"Muscular Diseases","Autoimmune","Autoimmune Diseases","Autoimmune Diseases of the Nervous System","Myasthenia Gravis","Muscle Weakness",[105,106,107,108,109,110,111,112,102,113,114,115,116,117,118,119],"ARC-311","CART","CAR-T","BCMA","Anito-cel","Generalized Myasthenia Gravis","gMG","MG","non-oncology plasma cell","autoimmune","auto-antibody","chimeric antigen receptor","D-Domain chimeric antigen receptor","B-cell maturation antigen (BCMA)","anitocabtagene autoleucel","2026-02-24",{"date":122,"type":46},"2026-02-25",{"date":124,"type":46},"2025-04-30",{"date":126,"type":23},"2028-04",{"name":128,"class":85},"Arcellx, Inc.",13,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":17,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":54},"100582682","validation-and-scaling-of-screening-program-for-undiagnosed-myasthenia-gravis-social-media-campaign-paired-with-a-self-moderated-assessment-100582682","NCT06866483","Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment","Inclusion Criteria:\n\n* Reside within the 50 states of the United States at the time of enrollment\n* Age 19 or older if reside in Nebraska or Alabama, Age 21 or older if reside in Mississippi, Age 18 years or older if reside in any other state\n* Active email account\n* Fluency in English (spoken \u002F written), as demonstrated by the ability to read and sign the Informed Consent Form\n\nExclusion Criteria:\n\n* Live in an overseas territory of the United States\n* Inability or unwillingness to provide written informed consent\n* Diagnosed myasthenia gravis, including sero-negative MG\\*\n* Diagnosed multiple sclerosis\n* Have speech impairment, eye\u002Farm\u002Fleg weakness due to diagnosed brain cancer, or stroke",{"count":137,"type":23},1000,"OBSERVATIONAL","This study expands and validates the pilot study NCT06381284. It is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The primary objective is to determine the validity of a self-assessment tool in encouraging undiagnosed participants, recruited through a social media campaign, to seek medical evaluation for suspected myasthenia gravis (MG).",[102,141,41],"Neuromuscular Disease",[143,144],"social media","myasthenia gravis","2025-03-04",{"date":147,"type":46},"2025-03-10",{"date":149,"type":46},"2025-02-26",{"date":151,"type":23},"2025-12-31",{"name":153,"class":85},"ZS Associates"]